Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.41 CAD 0.71% Market Closed
Market Cap: 140.3m CAD

Cardiol Therapeutics Inc
Net Issuance of Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cardiol Therapeutics Inc
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Net Issuance of Debt
-CA$55.4k
CAGR 3-Years
-3%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Net Issuance of Debt
-$323m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Net Issuance of Debt
-CA$347.2m
CAGR 3-Years
-563%
CAGR 5-Years
-129%
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
Net Issuance of Debt
-CA$39.2m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Net Issuance of Debt
CA$40.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
140.3m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
HIDDEN
Show

See Also

What is Cardiol Therapeutics Inc's Net Issuance of Debt?
Net Issuance of Debt
-55.4k CAD

Based on the financial report for Sep 30, 2025, Cardiol Therapeutics Inc's Net Issuance of Debt amounts to -55.4k CAD.

What is Cardiol Therapeutics Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
-2%

Over the last year, the Net Issuance of Debt growth was -29%. The average annual Net Issuance of Debt growth rates for Cardiol Therapeutics Inc have been -3% over the past three years , -2% over the past five years .

Back to Top